

Ina Hh Benoy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3341634/publications.pdf>

Version: 2024-02-01

74
papers

4,652
citations

156536

32
h-index

111975

67
g-index

74
all docs

74
docs citations

74
times ranked

5964
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of Self-Sampling for Cervical Cancer Screening: Diagnostic Test Properties of Three Tests for the Diagnosis of HPV in Rural Communities of Cuenca, Ecuador. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4619.	1.2	9
2	Development and validation of a wart-associated human papilloma virus genotyping assay for detection of HPV in cutaneous warts. <i>Journal of Medical Virology</i> , 2021, 93, 3841-3848.	2.5	2
3	High-risk human papillomavirus detection in self-collected vaginal samples compared with healthcare worker collected cervical samples among women attending gynecology clinics at a tertiary hospital in Pretoria, South Africa. <i>Virology Journal</i> , 2021, 18, 192.	1.4	2
4	Evaluation of ILEX SelfCerv for Detection of High-Risk Human Papillomavirus Infection in Gynecology Clinic Attendees at a Tertiary Hospital in South Africa. <i>Journal of Clinical Medicine</i> , 2021, 10, 4817.	1.0	5
5	Human Papillomavirus Prevalence in Oral and Oropharyngeal Rinse and Gargle Specimens of Dental Patients and of an HIV-Positive Cohort from Pretoria, South Africa. <i>Advances in Virology</i> , 2020, 2020, 1-10.	0.5	5
6	Efficacy of AV2-Salicylic acid combination therapy for cutaneous warts: Study protocol for a single-center randomized controlled trial. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100534.	0.5	8
7	Prevalence and Distribution of Human Papillomavirus Genotypes Among Women in Kinshasa, The Democratic Republic of the Congo. <i>Journal of Global Oncology</i> , 2019, 5, 1-9.	0.5	16
8	Prevalence and genotype-specific distribution of human papillomavirus in Burundi according to HIV status and urban or rural residence and its implications for control. <i>PLoS ONE</i> , 2019, 14, e0209303.	1.1	14
9	Using the VALGENT-3 framework to assess the clinical and analytical performance of the RIATOL qPCR HPV genotyping assay. <i>Journal of Clinical Virology</i> , 2019, 120, 57-62.	1.6	12
10	Accuracy of genotyping for HPV16 and 18 to triage women with low-grade squamous intraepithelial lesions: a pooled analysis of VALGENT studies. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 543-551.	1.5	11
11	The Positive Predictive Value of High-Grade Squamous Intraepithelial Lesion on Cytology for the Histological Diagnosis of Cervical Intraepithelial Neoplasia 2 or Higher: A Systematic Review. <i>Acta Cytologica</i> , 2019, 63, 206-214.	0.7	8
12	Performance of OncoE6 TM Cervical Test in detecting cervical precancer lesions in HIV-positive women attending an HIV clinic in Bujumbura, Burundi: a cross-sectional study. <i>BMJ Open</i> , 2019, 9, e029088.	0.8	8
13	A randomized, controlled trial of two strategies of offering the home-based HPV self-sampling test to non-participants in the Flemish cervical cancer screening program. <i>International Journal of Cancer</i> , 2018, 143, 861-868.	2.3	34
14	Human papilloma virus infection in HIV-infected women in Belgium: implications for prophylactic vaccines within this subpopulation. <i>European Journal of Cancer Prevention</i> , 2018, 27, 46-53.	0.6	5
15	Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening. <i>Virology Journal</i> , 2018, 15, 166.	1.4	9
16	VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples. <i>Journal of Clinical Virology</i> , 2018, 107, 52-56.	1.6	72
17	A high resolution melting (HRM) technology-based assay for cost-efficient clinical detection and genotyping of herpes simplex virus (HSV)-1 and HSV-2. <i>Journal of Virological Methods</i> , 2017, 248, 181-186.	1.0	11
18	Prevalence of high-risk human papillomavirus and abnormal pap smears in female sex workers compared to the general population in Antwerp, Belgium. <i>BMC Public Health</i> , 2016, 16, 477.	1.2	14

#	ARTICLE	IF	CITATIONS
19	Identification of human papillomavirus types causing lesions in penile cancerous, pre-cancerous and benign lesions using laser microdissection. <i>International Journal of Infectious Diseases</i> , 2016, 45, 444.	1.5	0
20	Cytology at the Time of HPV: Some Things to Think about when Discussing HPV. <i>Acta Cytologica</i> , 2016, 60, 527-533.	0.7	3
21	Evaluation of a standardised real-time PCR based DNA-detection method (Realstar [®]) in whole blood for the diagnosis of primary human cytomegalovirus (CMV) infections in immunocompetent patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2016, 35, 245-249.	1.3	10
22	Surveillance of effects of HPV vaccination in Belgium. <i>Cancer Epidemiology</i> , 2016, 41, 152-158.	0.8	20
23	VALGENT: A protocol for clinical validation of human papillomavirus assays. <i>Journal of Clinical Virology</i> , 2016, 76, S14-S21.	1.6	123
24	Detection, genotyping and quantitation of multiple hpv infections in south african women with cervical squamous cell carcinoma. <i>Journal of Medical Virology</i> , 2015, 87, 1594-1600.	2.5	15
25	Laser micro-dissection and qPCR for identifying specific HPV types responsible for malignancy in penile lesions. <i>Journal of Medical Virology</i> , 2015, 87, 1761-1768.	2.5	1
26	Early effects of human papillomavirus vaccination in Belgium. <i>European Journal of Cancer Prevention</i> , 2015, 24, 340-342.	0.6	10
27	High frequency of genital human papillomavirus infections and related cervical dysplasia in adolescent girls in Belgium. <i>European Journal of Cancer Prevention</i> , 2014, 23, 288-293.	0.6	5
28	Prevalence and viral load of 51 genital human papillomavirus types and three subtypes. <i>International Journal of Cancer</i> , 2013, 132, 2395-2403.	2.3	45
29	Viral Load of High-Risk Human Papillomaviruses as Reliable Clinical Predictor for the Presence of Cervical Lesions. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 406-414.	1.1	43
30	Multiple Human Papillomavirus Infections with High Viral Loads Are Associated with Cervical Lesions but Do Not Differentiate Grades of Cervical Abnormalities. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1458-1464.	1.8	93
31	Screening for Cervical Cancer Precursors With p16/Ki-67 Dual-Stained Cytology: Results of the PALMS Study. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1550-1557.	3.0	168
32	Clinical Validation of a Type-Specific Real-Time Quantitative Human Papillomavirus PCR against the Performance of Hybrid Capture 2 for the Purpose of Cervical Cancer Screening. <i>Journal of Clinical Microbiology</i> , 2012, 50, 4073-4077.	1.8	41
33	Changes in type-specific human papillomavirus load predict progression to cervical cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 3096-3104.	1.6	48
34	High-throughput detection, genotyping and quantification of the human papillomavirus using real-time PCR. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 655-61.	1.4	59
35	Serum Epstein-Barr virus (EBV) viral load can be a complementary sensitive test in primary Epstein-Barr virus infection. <i>Journal of Clinical Virology</i> , 2011, 50, 184-185.	1.6	10
36	Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer. <i>British Journal of Cancer</i> , 2011, 104, 1472-1477.	2.9	22

#	ARTICLE	IF	CITATIONS
37	Prior knowledge of HPV status improves detection of CIN2+ by cytology screening. American Journal of Obstetrics and Gynecology, 2011, 205, 569.e1-569.e7.	0.7	45
38	Type-specific HPV genotyping improves detection of recurrent high-grade cervical neoplasia after conisation. International Journal of Cancer, 2011, 129, 903-909.	2.3	50
39	BD-ProExC as Adjunct Molecular Marker for Improved Detection of CIN2+ after HPV Primary Screening. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 628-637.	1.1	45
40	Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. British Journal of Cancer, 2010, 102, 276-284.	2.9	167
41	Nucleic Acid Sequence-Based Amplification Assay for Human Papillomavirus mRNA Detection and Typing: Evidence for DNA Amplification. Journal of Clinical Microbiology, 2010, 48, 2524-2529.	1.8	30
42	Abstract P3-02-10: Comparison of Circulating Tumour Cells in Peripheral and Central Venous Blood of Patients with Metastatic Breast Cancer: A Pilot Study. , 2010, , .		0
43	Prevaccination Distribution of Human Papillomavirus Types in Women Attending at Cervical Cancer Screening in Belgium. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 321-330.	1.1	53
44	Human Papillomavirus 16 Load and E2/E6 Ratio in HPV16-Positive Women: Biomarkers for Cervical Intraepithelial Neoplasia ≥ 2 in a Liquid-Based Cytology Setting?. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2992-2999.	1.1	46
45	Re: Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells. Journal of the National Cancer Institute, 2009, 101, 895-896.	3.0	6
46	Quality control for normal liquid-based cytology: Rescreening, high-risk HPV targeted reviewing and/or high-risk HPV detection?. Journal of Cellular and Molecular Medicine, 2009, 13, 4051-4060.	1.6	14
47	Prognostic Significance of Real-Time RT-PCR Detection of Disseminated Tumour Cells in Bone Marrow and Circulating Tumour Cells in Patients with Breast Cancer.. , 2009, , .		0
48	Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. Journal of Cellular and Molecular Medicine, 2007, 11, 881-891.	1.6	100
49	Detection of circulating tumour cells in blood by quantitative real-time RT-PCR: effect of pre-analytical time. Clinical Chemistry and Laboratory Medicine, 2006, 44, 1082-7.	1.4	29
50	Improved endocervical sampling and HPV viral load detection by Cervex-Brush $\frac{1}{2}$ Combi. Cytopathology, 2006, 17, 374-381.	0.4	54
51	Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. British Journal of Cancer, 2006, 94, 672-680.	2.9	148
52	Prognostic Significance of Disseminated Tumor Cells as Detected by Quantitative Real-Time Reverse-Transcriptase Polymerase Chain Reaction in Patients with Breast Cancer. Clinical Breast Cancer, 2006, 7, 146-152.	1.1	27
53	Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer. Breast Cancer Research, 2005, 7, R210-9.	2.2	32
54	Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification. Clinical Cancer Research, 2004, 10, 7965-7971.	3.2	215

#	ARTICLE	IF	CITATIONS
55	Increased Serum Interleukin-8 in Patients with Early and Metastatic Breast Cancer Correlates with Early Dissemination and Survival. <i>Clinical Cancer Research</i> , 2004, 10, 7157-7162.	3.2	309
56	Real-time RT-PCR correlates with immunocytochemistry for the detection of disseminated epithelial cells in bone marrow aspirates of patients with breast cancer. <i>British Journal of Cancer</i> , 2004, 91, 1813-1820.	2.9	53
57	Circulating Basic Fibroblast Growth Factor is Partly Derived from the Tumour in Patients with Colon, Cervical and Ovarian Cancer. <i>Angiogenesis</i> , 2004, 7, 29-32.	3.7	11
58	Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. <i>International Journal of Cancer</i> , 2003, 103, 642-646.	2.3	365
59	Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. <i>British Journal of Cancer</i> , 2003, 88, 718-725.	2.9	151
60	Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. <i>British Journal of Cancer</i> , 2002, 86, 389-395.	2.9	175
61	Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. <i>British Journal of Cancer</i> , 2002, 87, 1437-1444.	2.9	52
62	The importance of the VEGF-load in platelets in cancer patients. <i>Annals of Oncology</i> , 2002, 13, 1689.	0.6	6
63	Serum Interleukin 6, Plasma VEGF, Serum VEGF, and VEGF Platelet Load in Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2002, 2, 311-315.	1.1	147
64	Importance of platelets in VEGF-mediated angiogenesis in tumors. <i>FEBS Letters</i> , 2002, 520, 182-182.	1.3	3
65	Platelets and vascular endothelial growth factor (VEGF): a morphological and functional study. <i>Angiogenesis</i> , 2001, 4, 37-43.	3.7	106
66	Correspondence re: M. L. George et al., Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? <i>Clin. Cancer Res.</i> , 6: 3147-3152, 2000. <i>Clinical Cancer Research</i> , 2001, 7, 1481-3.	3.2	5
67	Serum vascular endothelial growth factor load and interleukin-6 in cancer patients – reply. <i>British Journal of Cancer</i> , 2000, 82, 1896-1896.	2.9	8
68	Blood platelets and serum VEGF in cancer patients. <i>British Journal of Cancer</i> , 1999, 79, 370-376.	2.9	52
69	Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. <i>British Journal of Cancer</i> , 1999, 80, 892-897.	2.9	150
70	Plasma D-dimer levels, serum VEGF, b-FGF and IL-6 in metastatic breast cancer (MBC): correlation with tumour load and response to therapy. <i>European Journal of Cancer</i> , 1999, 35, S103.	1.3	0
71	THE EFFECTS OF PSYCHOLOGICAL STRESS ON HUMANS: INCREASED PRODUCTION OF PRO-INFLAMMATORY CYTOKINES AND Th1-LIKE RESPONSE IN STRESS-INDUCED ANXIETY. <i>Cytokine</i> , 1998, 10, 313-318.	1.4	653
72	Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. <i>British Journal of Cancer</i> , 1997, 76, 238-243.	2.9	262

#	ARTICLE	IF	CITATIONS
73	Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. <i>Annals of Oncology</i> , 1996, 7, 843-848.	0.6	121
74	Evolution of human papilloma virus prevalence in a highly vaccinated region in Belgium: a retrospective cohort study in Flemish women (2010–2019). <i>European Journal of Cancer Prevention</i> , 0, Publish Ahead of Print, .	0.6	1